Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 1/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 7/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6599493 | 0.85 | KDM2B (0.46) | KDM2BMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6599241 | 0.82 | OPRD1 (0.54) | KDM2BOPRM1OPRK1 | |
| SCHEMBL6598528 | 0.71 | SLC6A2 (0.41) | CXCR3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL11551982 | 0.67 | SLC6A4 (0.62) | KDM2BSLC6A4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL8792919 | 0.67 | MEN1 (0.48) | KDM2BSLC6A4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL8792928 | 0.67 | MEN1 (0.48) | KDM2BSLC6A4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11182951 | 0.66 | OPRM1 (0.72) | KDM2BSLC6A4MEN1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11549862 | 0.66 | SLC6A4 (0.61) | KDM2BSLC6A4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11534790 | 0.66 | OPRM1 (0.72) | KDM2BSLC6A4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11182953 | 0.66 | OPRM1 (0.72) | KDM2BSLC6A4MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140835-B1 | 3,3-BIARYLPIPERIDINE AND 2,2-BIARYLMORPHOLINE DERIVATIVES | PFIZER PROD INC (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20040063940-A1 | 3,3-Biarylpiperidine and 2,2-biarylmorpholine derivatives | PFIZER INC | 2004-04-01 | — | — | US | disclosed |
| US-6586431-B1 | Treating drug abuse and drug dependence; nervous system and gastrointestinal disorders | PFIZER INC | 2003-07-01 | — | — | US | disclosed |
| US-6503905-B1 | Treating nervous system and gastrointestinal disorders; analgesics, antiasthmatics | PFIZER INC | 2003-01-07 | — | — | US | disclosed |
| EP-1140835-A1 | 3,3-BIARYLPIPERIDINE AND 2,2-BIARYLMORPHOLINE DERIVATIVES | Pfizer Products Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039091-A1 | 3,3-BIARYLPIPERIDINE AND 2,2-BIARYLMORPHOLINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063940-A1 | 3,3-Biarylpiperidine and 2,2-biarylmorpholine derivatives | BCHE, HTR3C, CHRM2 | CXCR3 897/4885KDM2B 3771/4885SLC6A4 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.